Chippenham Hospital
January 15, 2018

Richmond, Va. (Jan. 15, 2018) — The Sarah Cannon Cancer Institute at HCA Virginia’s Johnston-Willis and Henrico Doctors’ Hospitals will participate in a new study, called STRIVE, which focuses on developing a test for early breast cancer detection.

The STRIVE Study is designed to determine if a blood test can complement mammography screenings by identifying genetic material arising from tumors to help discover breast cancer at its earliest stages.

“We are excited to offer one of the largest clinical research studies ever conducted in genomic medicine,” said Melanie DeHart, M.D., lead breast radiologist at The Breast Center, Sarah Cannon Cancer Institute at Henrico Doctors’ Hospital. “STRIVE will help guide healthcare decisions by providing more information, enhancing our abilities to detect cancer at earlier stages and reducing uncertainties for more women in our surrounding communities.”

The study, sponsored by GRAIL, Inc., is seeking to enroll 120,000 women across participating sites. Women who volunteer to participate will provide a blood sample and complete a short questionnaire at the time of their regular screening mammogram. In addition, participants will be followed and their health records will be monitored for up to five years for new cancer diagnoses.

“The earlier breast cancer is detected, the higher the chance of successful treatment,” said DeHart. “While mammograms have been the gold standard for breast cancer screening, additional tools combined with advanced technology can help make a bigger difference in saving more lives.”

The study also will be offered to women undergoing screening mammograms at other HCA Sarah Cannon locations including TriStar Summit Medical Center and TriStar Centennial Medical Center in Nashville, Tenn., and Centerpoint Medical Center and Menorah Medical Center in Kansas City, Mo. For more information on the STRIVE Study, to see the list of participating sites or to learn more, visit, email or call 1-833-I-STRIVE (833-478-7483).

GRAIL, Inc. is a life sciences company whose mission is to detect cancer early when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials and state of the art computer science and data science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. For more information, visit

About Sarah Cannon

Sarah Cannon, the Cancer Institute of HCA Healthcare, offers integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the United States and United Kingdom. Sarah Cannon’s cancer programs include individualized patient navigation provided by oncology-trained nurses, more than 1,000 stem cell transplants performed annually throughout the Sarah Cannon Blood Cancer Network, hundreds of clinical trials, and molecular profiling capabilities. Through its services, Sarah Cannon is providing state-of-the-art cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center. To learn more about Sarah Cannon, visit

About HCA Virginia

As the commonwealth’s most comprehensive provider network, HCA Virginia Health System operates 14 hospitals, 29 outpatient centers, five freestanding emergency rooms, and two urgent care centers and is affiliated with 3,000 physicians. It is one of Virginia’s largest employers, provides $251.6 million in uncompensated care and pays $82.3 million in state and local taxes each year. HCA Virginia includes five imaging centers, three outpatient surgery centers, four freestanding emergency rooms, and seven hospitals – Chippenham, Henrico Doctors’, John Randolph, Johnston-Willis, Parham Doctors’, Retreat Doctors’, and Spotsylvania Regional.